Earnings Feed
Start Free
Home/Filings/4/0001181431-13-014237
4//SEC Filing

Borland Scott 4

Accession 0001181431-13-014237

CIK 0001401923other
View on SEC.govCompany Profile

Filed

Mar 3, 7:00 PM ET

Accepted

Mar 4, 8:13 PM ET

Size

54.2 KB

Accession

0001181431-13-014237

Insider Transaction Report

Form 4
Period: 2013-03-01
MAP Pharmaceuticals, Inc.MAPP
Borland Scott
SVP, Neurology Franchise
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2013-03-01−1,800→ 0 total
    Exercise: $16.15Exp: 2021-01-25→ Common Stock (1,800 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2013-03-01−3,000→ 0 total
    Exercise: $14.09Exp: 2022-01-24→ Common Stock (3,000 underlying)
  • Disposition to Issuer

    Restricted Stock Unit (RSU)

    2013-03-01−750→ 0 total
    Exp: 2016-01-25→ Common Stock (750 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2013-03-01−1,589→ 0 total
    Exercise: $6.39Exp: 2017-05-01→ Common Stock (1,589 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2013-03-01−51,500→ 0 total
    Exercise: $10.37Exp: 2019-02-10→ Common Stock (51,500 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2013-03-01−21,000→ 0 total
    Exercise: $16.15Exp: 2021-01-25→ Common Stock (21,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2013-03-01−248→ 0 total
    Exercise: $3.36Exp: 2017-03-05→ Common Stock (248 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2013-03-01−4,237→ 0 total
    Exercise: $6.39Exp: 2017-05-01→ Common Stock (4,237 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2013-03-01−5,000→ 0 total
    Exercise: $10.37Exp: 2019-02-10→ Common Stock (5,000 underlying)
  • Disposition to Issuer

    Restricted Stock Unit (RSU)

    2013-03-01−3,375→ 0 total
    Exp: 2015-06-07→ Common Stock (3,375 underlying)
  • Disposition to Issuer

    Restricted Stock Unit (RSU)

    2013-03-01−300→ 0 total
    Exp: 2015-01-26→ Common Stock (300 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2013-03-01−32,500→ 0 total
    Exercise: $14.09Exp: 2022-01-24→ Common Stock (32,500 underlying)
  • Disposition to Issuer

    Restricted Stock Unit (RSU)

    2013-03-01−8,250→ 0 total
    Exp: 2016-01-25→ Common Stock (8,250 underlying)
  • Disposition from Tender

    Common Stock

    2013-03-01$25.00/sh−12,951$323,775→ 0 total
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2013-03-01−1,648→ 0 total
    Exercise: $3.36Exp: 2017-03-05→ Common Stock (1,648 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2013-03-01−10,000→ 0 total
    Exercise: $13.12Exp: 2018-01-21→ Common Stock (10,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2013-03-01−35,000→ 0 total
    Exercise: $16.19Exp: 2020-02-01→ Common Stock (35,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2013-03-01−13,750→ 0 total
    Exercise: $15.38Exp: 2021-06-06→ Common Stock (13,750 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2013-03-01−2,500→ 0 total
    Exercise: $13.12Exp: 2018-01-21→ Common Stock (2,500 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2013-03-01−4,375→ 0 total
    Exercise: $16.19Exp: 2020-02-01→ Common Stock (4,375 underlying)
  • Disposition to Issuer

    Restricted Stock Unit (RSU)

    2013-03-01−3,500→ 0 total
    Exp: 2015-01-26→ Common Stock (3,500 underlying)
Footnotes (24)
  • [F1]These shares were tendered to Groundhog Acquisition, Inc. (the "Purchaser") pursuant to the Purchaser's offer to purchase all of the outstanding shares common stock (the "Common Stock") of MAP Pharmaceuticals, Inc. (the "Issuer") at a cash purchase price of $25.00 per share, without interest thereon, and less any applicable withholding taxes, subject to the terms described in the Offer to Purchase for Cash filed with the Securities and Exchange Commission on January 31, 2013 (the "Tender Offer") and the Agreement and Plan of Merger, dated as of January 22, 2013, by and among Allergan, Inc. ("Parent"), the Purchaser and the Issuer (the "Merger Agreement"). Such shares were purchased by the Purchaser pursuant to the Tender Offer on March 1, 2013, which is also the date of the closing of a merger by and among Parent, the Purchaser and the Issuer (the "Effective Time").
  • [F10]These options to purchase shares of the Common Stock, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $354,575.00, representing the number of shares of the Common Stock underlying such options multiplied by $25.00, less the aggregate price of the options as exercised.
  • [F11]These options to purchase shares of the Common Stock, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $5,365.98, representing the number of shares of the Common Stock underlying such options multiplied by $25.00, less the aggregate price of the options as exercised.
  • [F12]These options are held by the spouse of the reporting person. The reporting person disclaims beneficial ownership of the options except to the extent of his pecuniary interest therein.
  • [F13]These options to purchase shares of the Common Stock, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $78,851.84, representing the number of shares of the Common Stock underlying such options multiplied by $25.00, less the aggregate price of the options as exercised.
  • [F14]These options to purchase shares of the Common Stock, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $29,700.00, representing the number of shares of the Common Stock underlying such options multiplied by $25.00, less the aggregate price of the options as exercised.
  • [F15]These options to purchase shares of the Common Stock, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $73,150.00, representing the number of shares of the Common Stock underlying such options multiplied by $25.00, less the aggregate price of the options as exercised.
  • [F16]These options to purchase shares of the Common Stock, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $38,543.75, representing the number of shares of the Common Stock underlying such options multiplied by $25.00, less the aggregate price of the options as exercised.
  • [F17]These options to purchase shares of the Common Stock, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $15,930.00, representing the number of shares of the Common Stock underlying such options multiplied by $25.00, less the aggregate price of the options as exercised.
  • [F18]These options to purchase shares of the Common Stock, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $32,730.00, representing the number of shares of the Common Stock underlying such options multiplied by $25.00, less the aggregate price of the options as exercised.
  • [F19]Each RSU represents a contingent right to receive one share of the Common Stock.
  • [F2]Includes shares held by the spouse of the reporting person. The reporting person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
  • [F20]These RSUs, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $87,500.00, representing the number of shares of the Common Stock underlying such RSUs multiplied by $25.00.
  • [F21]These RSUs, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $84,375.00, representing the number of shares of the Common Stock underlying such RSUs multiplied by $25.00.
  • [F22]These RSUs, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $206,250.00, representing the number of shares of the Common Stock underlying such RSUs multiplied by $25.00.
  • [F23]These RSUs, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $7,500.00, representing the number of shares of the Common Stock underlying such RSUs multiplied by $25.00.
  • [F24]These RSUs, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $18,750.00, representing the number of shares of the Common Stock underlying such RSUs multiplied by $25.00.
  • [F3]These options to purchase shares of the Common Stock, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $35,657.78, representing the number of shares of the Common Stock underlying such options multiplied by $25.00, less the aggregate price of the options as exercised.
  • [F4]These options to purchase shares of the Common Stock, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $29,571.77, representing the number of shares of the Common Stock underlying such options multiplied by $25.00, less the aggregate price of the options as exercised.
  • [F5]These options to purchase shares of the Common Stock, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $118,800.00, representing the number of shares of the Common Stock underlying such options multiplied by $25.00, less the aggregate price of the options as exercised.
  • [F6]These options to purchase shares of the Common Stock, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $753,445.00, representing the number of shares of the Common Stock underlying such options multiplied by $25.00, less the aggregate price of the options as exercised.
  • [F7]These options to purchase shares of the Common Stock, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $308,350.00, representing the number of shares of the Common Stock underlying such options multiplied by $25.00, less the aggregate price of the options as exercised.
  • [F8]These options to purchase shares of the Common Stock, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $185,850.00, representing the number of shares of the Common Stock underlying such options multiplied by $25.00, less the aggregate price of the options as exercised.
  • [F9]These options to purchase shares of the Common Stock, which became fully vested at the Effective Time, were canceled at the Effective Time in exchange for a cash payment of $132,275.00, representing the number of shares of the Common Stock underlying such options multiplied by $25.00, less the aggregate price of the options as exercised.

Documents

1 file

Issuer

MAP Pharmaceuticals, Inc.

CIK 0001401923

→
Entity typeother

Related Parties

1
  • filerCIK 0001527064

Filing Metadata

Form type
4
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 8:13 PM ET
Size
54.2 KB
View on SEC.gov